Frontiers of cardiovascular polypills: From atherosclerosis and beyond.
Frontiers of cardiovascular polypills: From atherosclerosis and beyond.
复制标题
DOI：
10.1016/j.tcm.2021.12.013
复制
发表时间：
2023-04
影响因子：
9.3
通讯作者：
Patel, Anushka
中科院分区：
文献类型：
--
作者：
Gnanenthiran, Sonali R.;Agarwal, Anubha;Patel, Anushka
固定剂量复方（FDC）疗法（也称为聚药丸）在临床实践中仍然未得到充分利用，尽管二十多年的随机对照试验证据表明，多药治疗的依从性增加，心血管疾病（CVD）风险因素控制改善，心血管事件发生率降低。有证据表明，基于FDC的实施战略可以在很大程度上补充和增强全球心血管疾病风险预防的现有战略。未来十年可能会扩大心血管FDC治疗的前沿，特别是考虑到FDC制造技术和可及性的预期进步。基于FDC的抗高血压治疗正在成为务实的降压策略的组成部分。心血管FDCs正在迅速走向成熟，从大肆宣传的研究工具转变为实用的临床工具。本综述评估了心血管FDCs的现有证据、当前使用的障碍和下一代潜在进展。
Fixed-dose combination (FDC) therapies (also known as polypills) remain underutilized in clinical practice despite over two decades of evidence from randomized controlled trials demonstrating increased adherence to multidrug therapy, improved cardiovascular disease (CVD) risk factor control, and lower incidence of cardiovascular events. Evidence demonstrates that FDC-based implementation strategies can substantially complement and augment current strategies for CVD risk prevention globally. The next decade is likely to extend the frontier of cardiovascular FDC therapies, particularly given expected advances in FDC manufacturing technology and accessibility. FDC-based anti-hypertensive therapies are emerging as integral components of a pragmatic blood pressure lowering strategy. Cardiovascular FDCs are rapidly approaching its coming of age, transforming from heavily hyped research tools to pragmatic clinical instruments. This review evaluates the current evidence for cardiovascular FDCs, barriers to current use, and potential next generation advances.
登录
查看更多内容
影响因子：
1.6
作者：
Abegaz TM;Shehab A;Gebreyohannes EA;Bhagavathula AS;Elnour AA
通讯作者：
Elnour AA
DOI：
10.1056/nejmoa1805819
发表时间：
2018-10-18
期刊：
The New England journal of medicine
影响因子：
--
作者：
McNeil JJ;Wolfe R;Woods RL;Tonkin AM;Donnan GA;Nelson MR;Reid CM;Lockery JE;Kirpach B;Storey E;Shah RC;Williamson JD;Margolis KL;Ernst ME;Abhayaratna WP;Stocks N;Fitzgerald SM;Orchard SG;Trevaks RE;Beilin LJ;Johnston CI;Ryan J;Radziszewska B;Jelinek M;Malik M;Eaton CB;Brauer D;Cloud G;Wood EM;Mahady SE;Satterfield S;Grimm R;Murray AM;ASPREE Investigator Group
通讯作者：
ASPREE Investigator Group
影响因子：
8.3
作者：
Gupta, Pankaj;Patel, Prashanth;Tomaszewski, Maciej
通讯作者：
Tomaszewski, Maciej
DOI：
10.1161/circheartfailure.120.008090
发表时间：
2021-03
期刊：
Circulation. Heart failure
影响因子：
--
作者：
Khan SS;Huffman MD;Shah SJ
通讯作者：
Shah SJ
影响因子：
10.8
作者：
Khaled, Shaban A.;Burley, Jonathan C.;Roberts, Clive J.
通讯作者：
Roberts, Clive J.